Navigation Links
Cellular Dynamics International Announces Launch of Initial Public Offering
Date:7/10/2013

MADISON, Wis., July 10, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc., a developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that it has commenced an initial public offering of 3,846,000 shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission ("SEC").  In addition, the underwriters will have a 30-day option to purchase up to an additional 576,900 shares of common stock from the Company. The initial public offering price is currently expected to be between $12.00 and $14.00 per share of common stock.

The Company intends to use the net proceeds that it receives in the offering for research and product development activities; sales and marketing activities, including expansion of its sales force to support the ongoing commercialization of its products; property, plant and equipment, including the build-out of its laboratory in California, and intellectual property; and for working capital and other general corporate purposes.

J.P. Morgan Securities LLC is acting as sole book-running manager for the offering, and Cowen and Company, LLC and Leerink Swann LLC are acting as co-managers.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering, and the final prospectus when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone (866) 803-9204.

Forward-looking Statements

This press release includes "forward-looking statements," including with respect to the proposed initial public offering and the Company's intended use of proceeds. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control. The forward-looking information presented in this press release is not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "plan," "seek," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

MEDIA CONTACTS:
Joleen Rau  
Senior Director, Marketing & Communications
Cellular Dynamics International, Inc.
608 310-5142
jrau@cellulardynamics.com 


'/>"/>
SOURCE Cellular Dynamics International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
2. Cellular Therapy and Cord Blood 2013 Market Report
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
5. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
6. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
7. Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
8. Top Genetic and Cellular Researchers Honored at ASGCT 16th Annual Meeting
9. Exit discovered in cellular garbage truck
10. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
11. Cellular Biomedicine Group Provides Update and 2013 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... coverage option for U.S. consumers who want to have ... DarioHealth has signed strategic alliance agreements with partners across ... coverage benefits, and if approved, will supply and bill ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research ... Stem Cell (hESC) Research - Global Strategic Business Report" report ... ... Cell (hESC) Research in US$ Million. Annual estimates and forecasts are ... are derived from primary and secondary research. The ...
(Date:3/24/2017)... Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company ... vaccines, today announced participation at the following conferences: ... and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at ... New York, NY . Agenus will participate in ... am: Robert B. Stein , M.D., Ph.D., President, ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
Breaking Biology Technology:
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
Breaking Biology News(10 mins):